Breaking News, Promotions & Moves

I-Mab Names Raj Kannan as CEO

Kannan has successfully led blockbuster product launches across several therapeutic areas including oncology.

I-Mab, a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of immunotherapies, appointed Raj Kannan CEO and a member of the board of directors, effective June 22, 2023. Kannan has more than 30 years of industry experience in creating and developing global specialty medicine franchises as a biotech CEO. Kannan has successfully led blockbuster product launches across several therapeutic areas including oncology both in the U.S. and globally....

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters